Skip to main content
. Author manuscript; available in PMC: 2010 Sep 15.
Published in final edited form as: Biochem Pharmacol. 2009 May 23;78(6):633–641. doi: 10.1016/j.bcp.2009.05.017

Figure 2.

Figure 2

Sequence of ODNs used in this study. M=5MeC. Inhibitors have modified target sites that contain either 5-azacytosine (Z) or zebularine aglycon (2P) bases in place of the cytosine (C) residue targeted for methylation (underlined).